Keyphrases
Acute Myeloid Leukemia
100%
Newly Diagnosed
100%
Phase II Trial
100%
Relapsed or Refractory Acute Myeloid Leukemia
100%
Intensive Chemotherapy
100%
Single Center
100%
Secondary Acute Myeloid Leukemia (sAML)
100%
Decitabine
100%
Venetoclax
100%
High Risk
33%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
22%
Duration of Response
22%
Overall Response Rate
22%
University of Texas
11%
MD Anderson Cancer Center
11%
Older Patients
11%
30-day Mortality
11%
Overall Survival
11%
Chronic Myeloid Leukemia
11%
Standard of Care
11%
Median Overall Survival
11%
Neutropenia
11%
Serious Adverse Events
11%
Safety Assessment
11%
White Blood Cell Count
11%
Febrile Neutropenia
11%
Improved Activity
11%
National Cancer Institute
11%
Response Assessment
11%
Treatment-related Adverse Events
11%
Pneumonia
11%
Myelodysplastic Syndrome
11%
Safety Profile
11%
Houston
11%
Pharmacodynamic Study
11%
Inhibitor Therapy
11%
New Standards
11%
Neutropenic Fever
11%
Newly Diagnosed Patients
11%
Previously Treated
11%
High Activity
11%
Sepsis
11%
Hypomethylating Agents
11%
One Dose
11%
Favorable Risk
11%
Core Binding Factor Leukemia
11%
Bcl-2 Inhibitor
11%
Risk Subset
11%
European LeukemiaNet
11%
End-organ Function
11%
U.S. National Institutes of Health
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Chemotherapy
100%
Decitabine
100%
Venetoclax
100%
Secondary Acute Myeloid Leukemia
50%
Malignant Neoplasm
11%
Overall Survival
11%
Adverse Event
11%
Febrile Neutropenia
11%
Diseases
5%
Infection
5%
Neutropenia
5%
Sepsis
5%
Chronic Myelomonocytic Leukemia
5%
Myelodysplastic Syndrome
5%
Pharmacodynamics
5%
Core Binding Factor
5%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Decitabine
100%
Venetoclax
100%
Secondary Acute Myeloid Leukemia
50%
Malignant Neoplasm
11%
Overall Survival
11%
Oncology
11%
Adverse Event
11%
Febrile Neutropenia
11%
Infection
5%
Diseases
5%
Neutropenia
5%
Cell Count
5%
Leukocyte
5%
Sepsis
5%
Myelodysplastic Syndrome
5%
Chronic Myelomonocytic Leukemia
5%
Pharmacodynamics
5%
Core Binding Factor
5%
Hypomethylating Agent
5%